Beprana (naproxcinod) / Nicox, Fera Pharma - LARVOL DELTA

Does Sex Affect the Efficacy of Systemic Pharmacological Treatments of Pain in Knee Osteoarthritis? (IASP 2024) - " Of 4574 citations screened, 9 studies (5201 participants) met inclusion criteria, analyzing drugs including duloxetine, etoricoxib, tapentadol, naproxcinod, lutikizumab, and rofecoxib. Available evidence is insufficient to evaluate differences in the analgesic response to pharmacological treatments of knee osteoarthritis between males and females. Current studies are limited by infrequent reporting of results by sex, small sample sizes, and insufficient statistical power. Our findings emphasize the need for more comprehensive research incorporating sex-stratified reporting and analysis to allow for future meta-analyses to determine whether sex-based differences exist."

Clinical • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • CRP

Does sex affect the efficacy of systemic pharmacological treatments of pain in knee osteoarthritis? A systematic review. (PubMed, Osteoarthr Cartil Open) - "9 studies (5201 participants) met inclusion criteria, analyzing drugs including duloxetine, etoricoxib, tapentadol, naproxcinod, lutikizumab, and rofecoxib. Current evidence does not support the existence of sex differences in the analgesic efficacy of systemic knee osteoarthritis treatments. However, this conclusion is substantially limited by the paucity of sex-specific reporting of results or subgroup analyses in most primary studies, emphasizing the need for future research to report on sex-stratified data to allow for comprehensive, personalized treatment strategies."

Journal • Review • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Nicox Second Quarter 2020 Business Update and Financial Highlights (GlobeNewswire) - "Following results from in vivo primary pharmacodynamics studies of naproxcinod in models of sickle-cell disease, U.S. partner Fera Pharmaceuticals decided to focus its development of naproxcinod on the treatment of painful vaso-occlusive crisis in sickle-cell disease. Fera plans to conduct further studies and other development activities in preparation for entering directly into a clinical efficacy trial of naproxcinod in sickle-cell patients, subject to being granted an ODD."

New trial • Sickle Cell Disease

Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy. (PubMed) - "In conclusion, this study shows that NO donation may have an important role, in addition to anti-inflammatory activity, in slowing down the progression of the disease in the mdx mouse model therefore positioning naproxcinod as a promising candidate for treatment of DMD."

Journal • Biosimilar • Fibrosis • Immunology • Inflammation • Systemic Sclerosis

Nicox’s Partner Fera Pharmaceuticals Files Application for Orphan Drug Designation for Naproxcinod in Sickle-Cell Disease (GlobeNewswire, NICOX) - "Nicox...and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced today that Fera has filed an application with the U.S. Food and Drug Administration (FDA) for an Orphan Drug Designation (ODD) for naproxcinod in sickle-cell disease....Fera plans to conduct further studies and other development activities in preparation for entering directly into a clinical efficacy trial of naproxcinod in sickle-cell patients, subject to being granted an ODD. "

New trial • Orphan drug